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To assess adherence to real-time changes in guidelines 
for infl uenza diagnosis and use of oseltamivir during the 
2009 infl uenza A(H1N1) pandemic, we reviewed medical 
records of patients with confi rmed or suspected infl uenza-
like illness (ILI) and those with no viral testing in a large 
Los Angeles (California, USA) hospital. Of 882 tested 
patients, 178 had results positive for infl uenza; 136 of the 
remaining patients received oseltamivir despite negative 
or no results. Oseltamivir use was consistent with national 
recommendations in >90%. Of inpatients, children were 
less likely than adults to have ILI at testing and to receive 
oseltamivir if ILI was found. Of outpatients, children were 
more likely to have positive test results; 20% tested did not 
have ILI or other infl uenza signs and symptoms. Twenty-
fi ve of 96 test-positive patients and 13 of 19 with lower 
respiratory tract disease were, inappropriately, not treated. 
Variations between practice and national recommendations 
could inform clinical education in future infl uenza seasons.
In April 2009, the novel infl uenza A(H1N1) pandemic infl uenza virus (infl uenza A[H1N1]pdm09) was 
identifi ed as the cause of infl uenza outbreaks. Infl uenza 
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 Infl uenza A(H1N1)pdm09 Infection 
disease caused by this strain rapidly spread, and in June 
2009, the World Health Organization (WHO) declared a 
global pandemic. Disease activity peaked during May–June 
2009, again in October 2009, and essentially disappeared 
by May 2010 (1–3). As with previous pandemics, the strain 
reemerged in the United States during the subsequent 
2010–2011 infl uenza season and accounted for ≈25% of 
characterized strains (4).
During the pandemic, the Centers for Disease Control 
and Prevention (CDC) issued several guidances for 
healthcare providers for the identifi cation and treatment 
of patients with suspected infl uenza A(H1N1)pdm09 
disease (Figure 1). Several rapid infl uenza diagnostic tests 
for identifi cation of the 2009 H1N1 strain were available, 
but their poor sensitivity soon became clear (5–7). CDC 
recommended that the neuraminidase inhibitor oseltamivir 
be used as a fi rst-line treatment during the pandemic (8). 
Available data suggested that the drug was clinically 
effective, but only when given within <48 hours of symptom 
onset (9–11). These guidelines changed during the course 
of the pandemic as real-time epidemiologic, virologic, and 
clinical data emerged (8,12–15).
CDC initially recommended priority use of 
antiviral drugs for only hospitalized patients and those 
at increased risk for infl uenza-related complications. 
This recommendation refl ected the knowledge that most 
persons infected with A(H1N1)pdm09 virus had self-
limited, mild-to-moderate disease; that commercial and 
stockpiled supplies of oseltamivir were limited; and that 
the development of resistance was a concern, particularly 
since no other effective and easily administered antiviral 
drugs were available (15–18). Questions remained, 
however, with regard to the overall risks and benefi ts and 
appropriate dosage of the drug for very young and obese 
patients. In September 2009, CDC advised that rapid 
infl uenza diagnostic tests be prioritized for patients who 
were hospitalized or for whom a diagnosis of infl uenza 
could inform clinical decision making. Furthermore, CDC 
reinforced the idea that presumptive treatment should be 
administered to this group of patients and expanded the 
target group for treatment to include outpatients with risk 
factors for severe disease, even when test results were 
unknown (5). Clinical judgment was clearly a key factor in 
the clinical management of patients with possible A(H1N1)
pdm09 disease.
Much has been published with regard to the 
epidemiology, virology, and clinical spectrum of A(H1N1)
pdm09 illness (19,20), but no information is available with 
regard to diagnostic and therapeutic decision making of 
physicians or their adherence to national guidelines for ill 
patients. We conducted this study to evaluate the adherence 
of physicians to contemporaneous national guidelines for 
diagnosis and use of oseltamivir among patients with 
suspected or confi rmed A(H1N1)pdm09 virus infection in 
the inpatient and outpatient settings.
Methods
The study population included all persons who accessed 
care from May 1 to December 31, 2009, at Harbor–UCLA 
Medical Center (HUMC) in Los Angeles, California. 
HUMC is a 538-bed, urban, academic, teaching hospital; 
it serves a diverse population, which is ≈55% Latino, 11% 
Caucasian, 24% black, 4% Asian, and 4% Pacifi c Islander.
We conducted a retrospective cohort study to 
evaluate 3 issues: 1) adherence of clinicians to national 
recommendations for use of osteltamivir among patients 
with suspected or confi rmed infl uenza virus infection; 2) 
appropriateness of patient selection for diagnostic testing; 
and 3) the  likelihood of clinicians to prescribe antiviral drug 
therapy for persons with known infl uenza-like illness (ILI) 
or lower respiratory tract infection (LRTI), 2 conditions for 
which CDC specifi cally recommended antiviral drug therapy. 
For the fi rst 2 objectives, we identifi ed child and adult 
inpatients and those seen in the emergency department with 
A(H1N1)pdm09 disease by using 4 overlapping data sources, 
including the following: 1) prospectively collected electronic 
A(H1N1)pdm09 virus laboratory-based surveillance data 
obtained by the HUMC clinical virology laboratory and 
the Infection Prevention and Control Department; 2) 
electronic, pharmacy-based oseltamivir utilization data; and 
3) data on point-of-care testing performed in the emergency 
department. These data were combined, and we reviewed the 
medical records of all patients with  a positive laboratory test 
for infl uenza in the outpatient setting and of  inpatients who 
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Figure 1. Centers for Disease 
Control and Prevention 
(CDC) guidance during the 
2009 pandemic of infl uenza 
A(H1N1)pdm09 disease. 
LRTI, lower respiratory tract 
infection.
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had a laboratory test that was positive for infl uenza virus or 
were prescribed oseltamivir. Approval for human subjects 
research was obtained from the Los Angeles Biomedical 
Research Institute. 
We performed a comprehensive review of medical 
records by using a standardized data collection instrument 
to identify demographic information and clinical 
characteristics of patients with the illness, including 
symptoms and signs and results of viral diagnostic 
testing and chest radiographs. Use of and indications for 
oseltamivir, including dose and duration of use, were 
recorded and, if oseltamivir was not prescribed, reasons for 
not using the drug were noted. We also recorded whether 
the patient exhibited risk factors for complications and 
death (from a preselected list that included concomitant 
cardiopulmonary, renal, liver, endocrine, blood, or 
metabolic disorders; immunosuppressive conditions; 
aspirin therapy; and neurologic conditions), diagnoses at 
admission or discharge, and length of stay.
We defi ned suspected infl uenza as illness in any 
patient for whom oseltamivir was prescribed by the treating 
clinician. We defi ned confi rmed infl uenza disease as illness 
in a patient with a positive laboratory test result for the 
virus. To evaluate adherence to guidelines, we used the 
contemporaneous CDC defi nition for ILI (fever and cough 
with or without sore throat) and defi ned severe illness as 
requiring intensive care, a documented oxygen saturation 
of <92%, or both.
To assess the  likelihood of clinicians to prescribe 
antiviral drug therapy for persons with known ILI or 
LRTI, we identifi ed all inpatients and outpatients with 
possible upper or lower respiratory tract infl uenza disease 
by using International Classifi cation of Diseases, Ninth 
Revision (ICD-9) diagnostic codes as follows: 079.89 
(viral infection), 079.99 (viral infection not otherwise 
specifi ed [NOS]), 460 (nasopharyngitis, acute), 462 
(pharyngitis, acute), 465.8 (infectious upper respiratory, 
multiple sites, acute), 465.9 (infectious upper respiratory, 
multiple sites, acute NOS), 466.0 (bronchitis, acute), 
466.19 (bronchiolitis, acute, due to other infectious 
organism), 478.9 (disease, upper respiratory /NOS), 
480.1 (pneumonia caused by respiratory syncytial 
virus), 480.8 (pneumonia caused by virus), 480.9 (viral 
pneumonia unspecifi ed), 484.8 (pneumonia in other 
infectious disease), 485 (bronchopneumonia, organism 
NOS), 486 (pneumonia, organism NOS), 487.0 (infl uenza 
with pneumonia), 487.1 (infl uenza with respiratory 
manifestation), 487.8 (infl uenza with manifestation), 
488.1 (infl uenza caused by identifi ed novel H1N1 
infl uenza virus), 490 (bronchitis NOS), 780.6 (fever), 
784.1 (pain, throat), 786.2 (cough) (21). The validity of 
the ICD-9–based ascertainment was assessed by using 
prospective emergency department triage ILI surveillance 
data collected beginning October 21, 2009, through the 
end of the study period.
From this group, we randomly selected 100 persons, 
stratifi ed by age (50 persons <18 and 50 >18 years of age) 
by using SAS 9.2, Proc Samplesurvey (SAS Institute, Cary, 
NC, USA). Using medical record review, we then identifi ed 
persons with ILI (defi ned above) or LRTI, defi ned by the 
presence of at least 1 specifi c lower respiratory tract sign, 
including tachypnea, retractions, or hypoxia (oxygen 
saturation <92%), and/or abnormal auscultatory fi ndings 
(crackles/crepitations or wheezing), and/or unequivocal 
and abnormal radiographic fi ndings.
We performed descriptive analyses of the above 
variables by using SAS version 9.2. Testing of proportions 
was performed by using χ2 or Fisher exact test as 
appropriate. All reported p values are 2-tailed and were 
considered signifi cant if p<0.05. 
Results
Entire Cohort
We identifi ed 882 patients who were tested for 
infl uenza virus during the study period, among whom 
178 (20%) tested positive. An additional 136 received 
oseltamivir but were not tested or had a negative laboratory 
test result for infl uenza virus. Overall, 232 (74%) of 314 
patients had ILI, and 82 (26%) of 314 had a positive test 
result for infl uenza virus but did not meet the CDC-defi ned 
criteria for ILI. Of these 82, 36 (44%) had other signs or 
symptoms consistent with infl uenza, such as headache, 
myalgia, nausea, or diarrhea. We identifi ed 218 (69%) 
inpatients among the 314 patients with confi rmed or 
suspected infl uenza. Of those 314 patients, 55 (18%) were 
<2 years of age, 129 (41%) were 2–18 years of age, 89 
(28%) were 19 to <50 years of age, 32 (10%) were 51 to 
<65 years of age, and 9 (3%) were >65 years of age. An 
underlying medical condition was recognized in 88 (48%) 
children (most commonly, asthma) and in 95 (52%) adults 
(most commonly, immunosuppression).
Oseltamivir was prescribed for 86 (66%) of 130 
children and 89 (87%) of 102 adults with ILI. Oseltamivir 
was prescribed at the correct dosage and duration of 
therapy for 229 (95%) of 240 patients, and 216 (90%) of 
240 patients received the drug <48 hours after symptom 
onset. Another 16 received the drug within 72 hours of 
disease onset. Severe illness was identifi ed in 132 (42%) 
of 314 patients, 118 (89%) of whom received oseltamivir 
(Figure 2).
Inpatients
Of 218 inpatients who received a diagnosis of or 
treatment for infl uenza, 107 (49%) were children, and 
111 (51%) were adults. Laboratory testing was performed 
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for 177 (81%) inpatients, and 74 (42%) were positive for 
infl uenza virus (Table). Oseltamivir was administered to 
198 (91%) of 218 inpatients, among whom 110 (50%) had 
a negative test or no laboratory testing performed. Of the 
remaining 88 with a positive test result, 5 did not receive 
oseltamivir because the patient refused, the patient was 
“well appearing,” or patient’s onset of symptoms occurred 
>48 hours before they received a diagnosis.
Of the inpatients, we identifi ed 68 (64%) of 107 
children and 86 (77%) of 111 adults who had ILI at the 
time of laboratory testing (p<0.04). Oseltamivir was given 
to 58 (85%) of the 68 children with ILI and 84 (98%) of 86 
adults with ILI (p<0.02). Oseltamivir was prescribed for 
145 (94%) of 155 inpatients with an underlying medical 
condition and for 118 (91%) of 129 patients with severe 
illness.
The median interval from illness onset to initiation 
of antiviral treatment was 2 days (range 1–8). The dosage 
or duration of therapy, or both, was incorrect for 11 (5%) 
inpatients; for 6 inpatients, no adjustment was made for 
renal insuffi ciency. Of those 6 inpatients, 2 had chronic renal 
insuffi ciency after a transplant, 1 had diabetic nephropathy, 
and 3 had pneumonia and renal insuffi ciency. Three obese 
patients received a doubled dose of oseltamivir.
Receipt of the vaccine against infl uenza A(H1N1)
pdm09 virus was documented in 61 (28%) of 218 patients, 
but 59 (97%) of them received the vaccine at hospital 
discharge. Only 1 patient had received the seasonal 
infl uenza vaccine before admission, and none received 
vaccine at discharge.
Outpatients
We identifi ed 664 patients who underwent rapid 
infl uenza diagnostic testing, of whom 77 (19%) of 
398 children and 19 (7%) of 266 adults tested positive 
(p<0.001). Twenty percent of tests were carried out on 
patients without CDC-defi ned ILI and for whom no other 
indication was present. As noted in Figure 3, only 11% 
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Figure 2. Total number of patients 
treated with oseltamivir by 
category, presence of infl uenza-
like illness (ILI), and disease 
severity, Los Angeles, California, 
USA, 2009. 
Table. Patients who underwent testing or treatment for influenza by category, Los Angeles, California, USA, 2009* 
Test results and treatment Inpatients† Outpatients‡ 
Influenza diagnostic test   
 Patients tested for influenza   
 Total  177/218 (81) 664/664 (100) 
 Adults 79/111 (71) 398/398 (100) 
 Children 98/107 (92) 266/266 (100) 
 Positive influenza test result   
 Total  74/177 (42) 96/664 (14) 
 Adults 18/79 (23) 19/398 (5) 
 Children 56/98 (57) 77/266 (29) 
 ILI among patients with a positive test result   
 Total  44/74 (59) 77/96 (80) 
 Adults 14/18 (78) 16/19 (84) 
 Children 30/56 (54) 61/77 (79) 
Oseltamivir prescribed   
 Patients with positive influenza test result 53/74 (72) 22/96 (23) 
 Patients with coexisting condition  145/155(94) 15/28 (54) 
 Patients with severe influenza disease  118/129 (91) 0/3 (0) 
 Median time from illness onset to treatment, d 2 (1–8) 2 (1–5)  
*Values are no./total no. (%) unless otherwise indicated. ILI, influenza-like illness.  
†For inpatients who received a diagnostic test for influenza, N = 218; for outpatients who received a diagnostic test, N = 664. For inpatients who received 
oseltamivir, N = 218. In the outpatient setting, study cohort was identified through diagnostic testing only. Use of oseltamivir was evaluated only among 
those for whom a diagnostic test result was positive (N = 96). 
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(73/664) of these tests were performed >2 weeks after CDC 
actively discouraged their use.
Oseltamivir was prescribed for 37 (48%) of 77 
outpatient children and 5 (26%) of 19 adults who tested 
positive for infl uenza (p>0.05), all at the appropriate 
dose and duration. As recommended, 35 (83%) of 42 
received the drug <48 hours from symptom onset, and 
the remaining patients received the drug within 72 hours 
of symptom onset. Of 54 (56%) of 96 patients who tested 
positive and did not receive oseltamivir, 25 (46%) were not 
treated according to CDC guidelines, and 8 (15%) refused 
therapy. The reasons for not initiating oseltamivir therapy 
included onset of symptoms >48 hours previously and 
lack of an underlying medical condition. For 21 (39%) of 
the untreated patients, we found no documentation of the 
reason for withholding therapy.
We found 3 outpatients who had severe illness, 
none of whom received oseltamivir, and the reasons for 
withholding therapy could not be determined. Conversely, 
16 (3%) of 522 patients with a negative test result received 
oseltamivir. The most common reasons documented for 
initiating therapy in this group included an underlying 
medical condition or concomitant diagnosis of pneumonia, 
ILI, or both, each consistent with CDC guidelines.
Therapy for Patients with ILI or LRTI Not 
Tested for Infl uenza Virus
We reviewed records of 50 randomly selected 
outpatients with ICD-9 codes for ILI who were not 
tested for infl uenza virus. Only 3 patients (6%) received 
oseltamivir (as recommended by CDC). Of the remainder 
who did not receive the drug, the duration of illness 
was >48 hours, the patient was “well appearing,” or no 
underlying risk factors were found. The median time from 
illness onset to obtaining medical attention was 3.7 days 
(range 0–14 days); 22 (44%) sought treatment within 
48 hours. Thirteen (26%) had an underlying medical 
condition (7 children and 6 adults). For each, however, 
there was an appropriate reason for withholding therapy, 
per CDC guidelines.
Among 50 outpatients with ILI and LRTI, 14 (28%) 
were admitted, 2 to the intensive care unit. The median 
time from illness onset to obtaining medical attention 
was 3 days (range 0–28 days); 31 (62%) of 50 sought 
treatment >48 hours after symptom onset. Eight of 
25 (32%) children and 5 (20%) of 25 adults received 
oseltamivir, and 6 patients received the drug <48 hours 
from symptom onset. Oseltamivir was administered to 6 
(38%) of 16 patients with severe illness and to 7 (25%) 
of 28 who had an underlying medical condition. The 
reason for not prescribing oseltamivir was documented 
in 5 charts, and the reasons included were that symptom 
onset was >48 hours from the visit to the hospital and 
that the patient was “well appearing.” Overall, 13 (68%) 
of 19 patients with LRTI who sought treatment within 
48 hours of illness onset did not receive oseltamivir as 
recommended by CDC.
Discussion
We believe that this study provides useful information 
with regard to the diagnostic and therapeutic behaviors of 
clinicians caring for patients with possible infl uenza virus 
infection. Although our data refl ect physician behavior 
during the 2009–10 infl uenza A (H1N1) pandemic, the 
fi ndings are likely applicable to any infl uenza year because 
diagnostic test performance, disease intensity, antiviral 
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Figure 3. Rapid infl uenza diagnostic testing (RIDT) performed for outpatients with infl uenza-like illness (ILI), Los Angeles, California, USA, 
2009.
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agent resistance, and virus strain affect clinical decision 
making each year.
We were interested in 2 general concepts: practice 
performance when infl uenza was clinically suspected 
and the potential for missed therapeutic opportunities 
when it was not. For the former, we found that providers’ 
practices were often consistent with CDC guidelines but 
notable defi ciencies were also identifi ed. In particular, a 
substantial proportion of potentially high-risk patients were 
not empirically treated, and a reason to withhold therapy 
could not be documented. This dynamic is similar to that 
for other medical conditions for which clinical practice 
guidelines are available: provider behavior at variance with 
the guideline may refl ect available patient-level information 
or other immediate concerns (22,23). In any case, we 
have identifi ed potential areas for targeted education of 
healthcare providers that should be supplemented by rapid 
dissemination and follow-up of national guidelines if and 
when they change over time.
We also found inconsistencies in the use of 
antiviral drug therapy, which was often at variance with 
contemporaneous guidelines. In our population, 25% 
of patients who received oseltamivir did not have ILI or 
another clear indication for treatment. During the pandemic, 
the drug was recommended for inpatients with ILI and 
outpatients with ILI and risk factors for severe illness if 
they had sought treatment within 48 hours of symptom 
onset (5). However, although too many outpatients without 
ILI received oseltamivir, too few (32%) received the drug 
despite having LRTI, a consistent indication for therapy. 
For most patients with LRTI, we could not identify a 
reasonable justifi cation for withholding therapy. Not 
surprisingly, all of these patients received antibacterial 
agents, yet it remains unclear whether the clinicians actively 
considered infl uenza virus as a primary pathogen or risk 
factor for the presumed bacterial superinfection. Infl uenza 
virus infection and its association with secondary bacterial 
infection is well documented with infl uenza A(H1N1)
pdm09 virus infection and with interepidemic disease 
(24–27). Treatment with antiviral drugs in this setting 
may lessen illness when superinfection exists (26,28). In 
this circumstance, greater recognition of the possibility of 
infl uenza virus infection and use of antiviral drug therapy 
may mitigate illness and lessen hospital costs (29,30).
We found that diagnostic practices were often 
inconsistent with contemporaneous guidelines. Nearly one 
third of patients were tested for infl uenza virus, despite 
the lack of ILI and ≈20% had no other indication for 
which testing might otherwise be justifi ed (e.g., headache, 
myalgia). Previous work has shown that relatively few 
patients with infl uenza virus infection have systemic signs 
without fever, sore throat, or cough (31). Although changes 
in CDC recommendations were quickly disseminated to 
hospital clinicians by management memo, email, or face-
to-face meetings, even more rapid communication and 
follow-up reminders may have enhanced adherence to 
guidelines.
We found that the dosage and duration of oseltamivir 
were generally consistent with CDC guidelines in ≈90% 
of all treated patients, and specifi cally for all outpatients. 
HUMC required the use of a preauthorization drug form 
that noted the appropriate age- and weight-based dose; 
an outpatient prescription for oseltamivir would not have 
been released without a completed form. Such tools have 
been shown to limit dosing errors (32,33). Also consistent 
with the CDC guidelines, >90% of hospitalized patients 
and patients with severe illness in our study received 
oseltamivir. Among outpatients, we noted that for ≈50%, 
an appropriate rationale for not providing oseltamivir was 
documented in the medical record.
Among the small number of dosing errors identifi ed, 
>40% were related to inappropriate adjustment for renal 
insuffi ciency. More than 90% of oseltamivir is metabolized 
to oseltamivir carboxylate, 99% of which is eliminated by 
renal excretion, thus requiring dosage adjustment in this 
setting. Antimicrobial drug dosing errors are common 
(34,35), and a failure to adjust for renal impairment is a 
frequent underlying reason (36,37). Although controlled 
data are not available, oseltamivir has been associated 
with the development of thrombocytopenia, particularly 
when renal clearance is artifi cially lowered by concomitant 
administration of the drug probenicid (38). Attention 
should be given to patients’ renal function, particularly in 
the elderly (diminished renal clearance) and in those for 
whom higher doses may be recommended, such as the 
severely ill or obese (8).
We identifi ed clinical management differences between 
how clinicians prescribed treatment for adult patients and 
how they prescribed treatment for children. Children who 
were inpatients were signifi cantly less likely to have ILI at 
the time of testing and to receive treatment for ILI. When 
testing was carried out, children were also more likely to 
test positive for infl uenza virus than were adults, possibly 
because of the higher virus load in this population. These 
data also may refl ect more overall testing of children, 
particularly young children who are more likely than adults 
to have nonspecifi c signs and symptoms (lethargy, poor 
feeding, abdominal pain) (39,40). In addition, infants and 
young children may not articulate symptoms of ILI (e.g., 
sore throat), leading to increased nonspecifi c testing and 
treatment of this population.
The main strength of this study is the comprehensive 
nature of case ascertainment, which included laboratory-
based information and review of all prospectively collected 
logs for emergency department point-of-care testing. 
However, some patients who underwent testing for 
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infl uenza virus may not have been noted in the outpatient 
log system. We appreciate that ICD-9 code data for ILI and 
LRTI may be nonspecifi c, but our prospectively collected 
ILI data (albeit for a limited portion of the surveillance 
period) validated the temporal trends for this diagnosis 
in the outpatient setting. We also did not include data 
from medical outpatient (nonemergency department) 
clinics where other patients with infl uenza may have 
been identifi ed and treated, perhaps skewing our data to 
those who were more ill. As a retrospective study, our 
conclusions depend solely upon information documented 
in the medical record, which may be incomplete. Also, the 
use of an antiviral agent authorization form most likely 
improved the dosing practice, as has been shown in other 
settings (32,33). Last, our study population includes only a 
single academic medical center and therefore may not be 
representative of the region or the nation.
To our knowledge, similar studies of physician 
behavior with regard to infl uenza disease, and for A(H1N1)
pdm09 disease in particular, have not been reported. We 
have identifi ed variations in clinical practice in relation to 
national guidelines that suggest potential areas of education 
for future infl uenza seasons.
This study was supported in part by the Los Angeles 
Biomedical Research Institute and the Los Angeles County 
Department of Health Services.
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